Dementia with Lewy bodies - a clinicopathological update.
暂无分享,去创建一个
T. Hortobágyi | D. Aarsland | A. Hye | J. Bencze | Woosung Seo | Abdul Hye
[1] Leonidas Stefanis,et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.
[2] C. Tanner,et al. Bowel movement frequency in late‐life and incidental Lewy bodies , 2007, Movement disorders : official journal of the Movement Disorder Society.
[3] I G McKeith,et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. , 1999, Brain : a journal of neurology.
[4] K Kosaka,et al. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease? , 1984, Clinical neuropathology.
[5] T. Hortobágyi,et al. Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. , 2019, Journal of Alzheimer's disease : JAD.
[6] J. Wiltfang,et al. Decreased CSF amyloid β42 and normal tau levels in dementia with Lewy bodies , 2000, Neurology.
[7] T. Hortobágyi,et al. Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer’s disease and neocortical Lewy body disease , 2019, Scientific Reports.
[8] Elizabeth Schroeder. Activity , 2005, Encyclopedic Dictionary of Archaeology.
[9] Clifford R Jack,et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.
[10] I G McKeith,et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. , 2000, The British journal of psychiatry : the journal of mental science.
[11] T. Hortobágyi,et al. Depressive Symptoms in Alzheimer’s Disease and Lewy Body Dementia: A One-Year Follow-Up Study , 2011, Dementia and Geriatric Cognitive Disorders.
[12] Dag Aarsland,et al. Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. , 2016, Parkinsonism & related disorders.
[13] M. Okano,et al. Cohort Study , 2020, Definitions.
[14] I G McKeith,et al. The role of levodopa in the management of dementia with Lewy bodies , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[15] D. Perl,et al. Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.
[16] G. Glover,et al. Altered cortical visual processing in PD with hallucinations , 2004, Neurology.
[17] K. Jellinger,et al. Post-mortem assessment in vascular dementia: advances and aspirations , 2016, BMC Medicine.
[18] W. M. van der Flier,et al. The use of EEG in the diagnosis of dementia with Lewy bodies , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[19] R. Melis,et al. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders , 2009, Alzheimer's & Dementia.
[20] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[21] T. Hortobágyi,et al. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias , 2014, Brain pathology.
[22] T Ota,et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET , 2009, Neurology.
[23] S. Pal,et al. The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies - a systematic review and meta-analysis. , 2013, Parkinsonism & related disorders.
[24] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[25] M. Cookson,et al. α‐Synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[26] T. Tokuda,et al. CSF α-synuclein levels in dementia with Lewy bodies and Alzheimer's disease , 2009, Brain Research.
[27] B. Mollenhauer,et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.
[28] B. Ghetti,et al. Early‐onset Dementia with Lewy Bodies , 2004, Brain pathology.
[29] T. Hortobágyi,et al. Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach , 2018, Brain : a journal of neurology.
[30] W. Hill,et al. Contribution of somal Lewy bodies to neuronal death , 1997, Brain Research.
[31] Hitoshi Takahashi,et al. The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.
[32] T. Hortobágyi,et al. Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia , 2016, Alzheimer's & Dementia.
[33] M. Onofrj,et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.
[34] K. Jellinger,et al. Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? , 2018, BMC Medicine.
[35] G. Plazzi,et al. A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. , 2011, Sleep medicine.
[36] T. Hortobágyi,et al. Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study , 2016, BMJ Open.
[37] H. Mori,et al. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. , 1994, Biochemical and biophysical research communications.
[38] Francesca Clerici,et al. Physical activity reduces the risk of dementia in mild cognitive impairment subjects: a cohort study. , 2014, Journal of Alzheimer's disease : JAD.
[39] T. Hortobágyi,et al. Early and Presenting Symptoms of Dementia with Lewy Bodies , 2011, Dementia and Geriatric Cognitive Disorders.
[40] Barbara B. Levin. on a Longitudinal Case Study , 2001 .
[41] Paul M. Thompson,et al. Hippocampal shape differences in dementia with Lewy bodies , 2008, NeuroImage.
[42] F. Lewy. Paralysis agitans. I. Pathologische Anatomie , 1912 .
[43] D. Allsop,et al. Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[44] K. Kosaka,et al. Diffuse lewy body disease in Japan , 1990, Journal of Neurology.
[45] Alan J. Thomas,et al. Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment , 2014, Neurobiology of Aging.
[46] C. Tanner,et al. Association of olfactory dysfunction with incidental Lewy bodies , 2006, Movement disorders : official journal of the Movement Disorder Society.
[47] T. Hortobágyi,et al. Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. , 2016, Brain : a journal of neurology.
[48] B. Boeve,et al. Lewy body dementias , 2015, The Lancet.
[49] V. Lee,et al. Modeling Lewy pathology propagation in Parkinson's disease. , 2014, Parkinsonism & related disorders.
[50] B. Dubois,et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. , 1995, Human molecular genetics.
[51] Dag Aarsland,et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. , 2005, The Journal of clinical psychiatry.
[52] M. Britton,et al. A One-Year Follow-up Study , 2005 .
[53] T. Tokuda,et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .
[54] T. Tokuda,et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease , 2010, Neurology.
[55] Dag Aarsland,et al. Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration , 2019, Acta neuropathologica communications.
[56] T. Hortobágyi,et al. Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer’s Disease , 2020, Brain sciences.
[57] K. Davis,et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.
[58] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[59] T. Hortobágyi,et al. Unfolded protein response is activated in Lewy body dementias , 2016, Neuropathology and applied neurobiology.
[60] The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.
[61] K. Heilman,et al. Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank , 2002, Alzheimer disease and associated disorders.
[62] J. Morris,et al. Greenfield's Neuropathology Edited by J. Hume-Adams and L. W. Ducken. Fifth edition. Oxford University Press, New York (1992), 1557pp. Price £145, U.S.$195 , 1993, Neuroscience.
[63] D. V. von Cramon,et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.
[64] T. Hortobágyi,et al. Behavioural and Psychological Symptoms in Neurocognitive Disorders: Specific Patterns in Dementia Subtypes , 2019, Open medicine.
[65] D. Dickson,et al. Incidental Lewy body disease and preclinical Parkinson disease. , 2008, Archives of neurology.
[66] J Q Trojanowski,et al. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. , 1991, The American journal of pathology.
[67] T. Hortobágyi,et al. Biological function of Lemur tyrosine kinase 2 (LMTK2): implications in neurodegeneration , 2018, Molecular Brain.
[68] B. Boeve,et al. REM Sleep Behavior Disorder in Parkinson’s Disease and Dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.
[69] J. Wiltfang,et al. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. , 2005, Dementia and geriatric cognitive disorders.
[70] B. Mollenhauer,et al. Biomarkers in biological fluids for dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.
[71] L. Ferini-Strambi,et al. REM Sleep Behavior Disorder (RBD) as a marker of neurodegenerative disorders. , 2014, Archives italiennes de biologie.
[72] Alan J. Thomas,et al. Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia , 2017, Journal of Alzheimer's disease : JAD.
[73] D. Maraganore,et al. Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? , 2011, Neurobiology of Aging.
[74] W. M. van der Flier,et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies , 2014, Human molecular genetics.
[75] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[76] J. Price,et al. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease , 2011, Neurology.
[77] Eric E. Smith,et al. The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[78] E. Perry,et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.
[79] D. Dickson,et al. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? , 2005, Parkinsonism & related disorders.
[80] A. Chincarini,et al. Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies , 2019, Movement disorders : official journal of the Movement Disorder Society.
[81] J. O'Brien,et al. Magnetic Resonance Imaging in Lewy Body Dementias , 2009, Dementia and Geriatric Cognitive Disorders.
[82] Alan J. Thomas,et al. Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia , 2014, F1000Research.
[83] K. Jellinger,et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease , 2002, Journal of Neural Transmission.
[84] B. Boeve,et al. Sleep in Parkinson’s Disease and Dementia with Lewy Bodies , 2012 .
[85] Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer’s disease , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[86] Tetsuya Mori,et al. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies , 2004, Annals of nuclear medicine.
[87] T. Bird,et al. Familial dementia with lewy bodies: a clinical and neuropathological study of 2 families. , 2002, Archives of neurology.
[88] J. Hoenicka,et al. The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.
[89] T. Hortobágyi,et al. Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. , 2017, Journal of Alzheimer's disease : JAD.
[90] L. Thal,et al. Cholinergic dysfunction in diseases with Lewy bodies , 2000, Neurology.
[91] S Noachtar,et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. , 2000, Brain : a journal of neurology.
[92] Charles DeCarli,et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.
[93] D. Galasko,et al. Reduced hypocretin (orexin) levels in dementia with Lewy bodies , 2010, Neuroreport.
[94] Ronald C Petersen,et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. , 2011, Sleep medicine.
[95] K. Ishii,et al. Regional cerebral blood flow difference between dementia with Lewy bodies and AD , 1999, Neurology.
[96] W. Schulz-Schaeffer. The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.
[97] P. Scheltens,et al. The significance of medial temporal lobe atrophy , 2007, Neurology.
[98] John-Paul Taylor,et al. Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies , 2015, Neurobiology of Aging.
[99] J. Rabe-Jabłońska,et al. [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.
[100] Alan J. Thomas,et al. Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.
[101] H. Shill,et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction , 2009, Acta Neuropathologica.
[102] S. Gabriel,et al. Systematic Review of the Literature , 2021, Adherence to Antiretroviral Therapy among Perinatal Women in Guyana.
[103] H. Braak,et al. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease , 2010, Acta Neuropathologica.
[104] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[105] E. Sinforiani,et al. Analysis of video‐polysomnographic sleep findings in dementia with Lewy bodies , 2013, Movement disorders : official journal of the Movement Disorder Society.
[106] O. Hoffmann,et al. Amyloid β Peptide and Precursor Protein (APP) in Mild and Severe Brain Ischemia , 1997 .
[107] F. Lebert,et al. [Treatment of dementia with Lewy bodies]. , 2006, Revue neurologique.
[108] Dag Aarsland,et al. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies , 2007, Neurology.
[109] B. Mollenhauer,et al. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies , 2016, Journal of Neurology.
[110] F. Hirth,et al. Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease , 2018, Front. Neurosci..
[111] E. Kuusisto,et al. Morphogenesis of Lewy Bodies: Dissimilar Incorporation of α‐Synuclein, Ubiquitin, and p62 , 2003, Journal of neuropathology and experimental neurology.
[112] T. Montine,et al. RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy‐Related Pathology in the Dementia Patient , 2008, Brain pathology.
[113] M. David,et al. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis , 2016, PloS one.
[114] D. Aarsland,et al. Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure , 2019, European Geriatric Medicine.
[115] I. McKeith,et al. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.
[116] Alan J. Thomas,et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. , 2015, The American journal of psychiatry.
[117] Andrew King,et al. Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium , 2009, Acta Neuropathologica.
[118] G Halliday,et al. pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium , 2009, Neuropathology and applied neurobiology.
[119] Robert Howard,et al. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. , 2006, Brain : a journal of neurology.
[120] Ludwig Kappos,et al. Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.
[121] B S Linn,et al. The Rapid Disability Rating Scale—2 , 1982, Journal of the American Geriatrics Society.
[122] Introduction to Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders , 2011 .
[123] E. Tolosa,et al. Multiple organ involvement by alpha‐synuclein pathology in Lewy body disorders , 2014, Movement disorders : official journal of the Movement Disorder Society.
[124] B. Mollenhauer,et al. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. , 2016, Biomarkers in medicine.
[125] Guy B. Williams,et al. Neuroimaging characteristics of dementia with Lewy bodies , 2014, Alzheimer's Research & Therapy.
[126] Henrik Zetterberg,et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. , 2016, JAMA neurology.
[127] D. Aarsland,et al. ( 123 I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study , 2013 .
[128] John O'Brien,et al. Neuroimaging of dementia with Lewy bodies. , 2012, Neuroimaging clinics of North America.
[129] Alan J. Thomas,et al. Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. , 2015, Journal of Alzheimer's disease : JAD.
[130] I. McKeith. Commentary: DLB and PDD: the same or different? Is there a debate? , 2009, International Psychogeriatrics.
[131] T. Hortobágyi,et al. Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features , 2011, International journal of geriatric psychiatry.
[132] W. F. Abdo,et al. CSF α-synuclein does not differentiate between parkinsonian disorders , 2012, Neurobiology of Aging.
[133] Eka Swadiansa. The hypothesis , 1990 .
[134] Dag Aarsland,et al. Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies , 2004, Journal of geriatric psychiatry and neurology.
[135] A. Kakita,et al. Relationship Among &agr;-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra , 2006, Journal of neuropathology and experimental neurology.
[136] H. Braak,et al. Staging of Sporadic Parkinson Disease-Related α-Synuclein Pathology: Inter- and Intra-Rater Reliability , 2005, Journal of neuropathology and experimental neurology.
[137] I. McKeith,et al. High prevalence of neurovascular instability in neurodegenerative dementias , 1998, Neurology.
[138] J. Morris,et al. Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.
[139] J. Kessler,et al. Task force WANTED: many reasons to promote research on cognitive rehabilitation to prevent, delay, and treat cognitive dysfunctions in patients with Parkinson's disease. , 2015, Parkinsonism & related disorders.